---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-24-000078"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:15:12.981079+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BD Q4 FY2024 revenue $5.4B (+6.9%), adjusted EPS $3.81 (+11.4%); issues FY25 EPS guidance $14.25-$14.60

## Summary
- Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).
- FY24 revenue $20.2B, +4.2%; adjusted EPS $13.14 (+7.6%); free cash flow $3.1B (+47.4%).
- FY25 guidance: organic revenue growth 4.0-4.5%; adjusted diluted EPS $14.25-$14.60 (midpoint ~10% growth).
- Completed acquisition of Edwards Lifesciences' Critical Care product group, expanding smart connected care portfolio.

## SEC filing metadata
- accession: 0000010795-24-000078
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/0000010795-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/bdx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-24-000078
- JSON: https://secwatch.observer/filing/0000010795-24-000078.json
- Plain text: https://secwatch.observer/filing/0000010795-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.